Cargando…

CARTmath—A Mathematical Model of CAR-T Immunotherapy in Preclinical Studies of Hematological Cancers

SIMPLE SUMMARY: CAR-T cell immunotherapy uses engineered T lymphocytes to recognize cancer antigens and to directly attack cancer cells and have been successfully used against cancers of hematopoietic origin. New CAR designs involving different and multiple target antigens and co-stimulatory structu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barros, Luciana R. C., Paixão, Emanuelle A., Valli, Andrea M. P., Naozuka, Gustavo T., Fassoni, Artur C., Almeida, Regina C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231202/ https://www.ncbi.nlm.nih.gov/pubmed/34208323 http://dx.doi.org/10.3390/cancers13122941

Ejemplares similares

Modeling Patient-Specific CAR-T Cell Dynamics: Multiphasic Kinetics via Phenotypic Differentiation
por: Paixão, Emanuelle A., et al.
Publicado: (2022)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

SINDy-SA framework: enhancing nonlinear system identification with sensitivity analysis
por: Naozuka, Gustavo T., et al.
Publicado: (2022)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies
por: Soldierer, Maren, et al.
Publicado: (2022)

A bioengineered immunocompetent human leukemia chip for preclinical screening of CAR T cell immunotherapy
por: Ma, Chao, et al.
Publicado: (2023)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Systematic Review of Available CAR-T Cell Trials around the World
por: Barros, Luciana Rodrigues Carvalho, et al.
Publicado: (2022)

Potential of Immunotherapies in Treating Hematological Cancer-Infection Comorbidities—A Mathematical Modelling Approach
por: Ottesen, Johnny T., et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
por: Fassoni, Artur C., et al.
Publicado: (2018)

Immunotherapy approaches for hematological cancers
por: Lanier, Olivia L., et al.
Publicado: (2022)

Immunotherapy Frontiers in Hematology
por: Hallam, Simon
Publicado: (2017)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

The Hematology of Tomorrow Is Here—Preclinical Models Are Not: Cell Therapy for Hematological Malignancies
por: Arranz, Lorena
Publicado: (2022)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Versatile CAR T-cells for cancer immunotherapy
por: Chu, Fuliang, et al.
Publicado: (2018)

Tuning the performance of CAR T cell immunotherapies
por: Richardson, Noah H., et al.
Publicado: (2019)

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018)

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
por: McCloskey, Curtis W., et al.
Publicado: (2018)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies
por: Stadtmauer, Edward, et al.
Publicado: (2017)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
por: Huang, Jiawen, et al.
Publicado: (2022)

Next generations of CAR-T cells - new therapeutic opportunities in hematology?
por: Tomasik, Jaromir, et al.
Publicado: (2022)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

CAR-T cell therapy for hematological malignancies: History, status and promise
por: Wang, Chao, et al.
Publicado: (2023)

Successful clinical translation of preclinical combinations of radiation and immunotherapy
por: Formenti, Silvia C., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_jag33kgsusffuh6buch7u64e90